Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Lih En Hong, Chung Hoow Kok, Monika Kutyna, Joule J Li, Rakchha Chhetri, David M. Ross, Susan Branford, Hamish S Scott, Anna Brown, Christopher Norman Hahn, David T Yeung, Mrinal M. Patnaik, Mithun V Shah, Susanna Proudman, Mihir Wechalekar, Devendra Hiwase

Blood (2023) 142 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2023-190809

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

Carl T. Shultz, Aref Al-Kali, Anmol Baranwal, Rakchha Chhetri, Elizabeth Ngoc Hoa Tran, Arini Arsana, Hassan B. Alkhateeb, Bradley Stish, Ayalew Tefferi, Mrinal M.M. Patnaik, Naseema Gangat, Devendra Hiwase, Mithun V. Shah

Blood (2022) 140 (Supplement 1): 6309–6311.

https://doi.org/10.1182/blood-2022-164769

Published: 2022

Journal Articles

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood (2022) 140 (Supplement 1): 9798–9799.

https://doi.org/10.1182/blood-2022-165859

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

Alia Cibich, Rakchha Chhetri, Kirsty M. Sharplin, Naranie Shanmuganathan, David T. Yeung, Deepak Singhal, Ashanka Mahilal Beligaswatte, Noemi Horvath, Philip Selby, Leanne Purins, Judith Stevens, Peter G. Bardy, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 4892–4893.

https://doi.org/10.1182/blood-2022-170726

Published: 2022

Journal Articles

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood (2022) 140 (Supplement 1): 6964–6965.

https://doi.org/10.1182/blood-2022-168349

Published: 2022

Journal Articles

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 6962–6963.

https://doi.org/10.1182/blood-2022-167978

Published: 2022

Journal Articles

Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy

Mithun V. Shah, Rakchha Chhetri, Ruchita Dholakia, Hassan B. Alkhateeb, Aref Al-Kali, Mrinal M. Patnaik, Naseema Gangat, Andrew H. Wei, Ing Soo Tiong, Kebede H. Begna, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 36.

https://doi.org/10.1182/blood-2021-147049

Published: 2021

Journal Articles

T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML

Mithun V. Shah, Rakchha Chhetri, Urshila Durani, Monika Kutyna, Hassan B. Alkhateeb, Mark R. Litzow, William J Hogan, Deepak Singhal, Siddarth Nayar, Ayalew Tefferi, Kebede H. Begna, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2021-152380

Published: 2021

Journal Articles

Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome

Christopher N Hahn, Simone K. Feurstein, Deepak Singhal, Monika M Kutyna, Rakchha Chhetri, Amilia Wee, Daniel Thomas, Hamish S Scott, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2021-154514

Published: 2021

Journal Articles

Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS

Jamie Choong, Monika M Kutyna, Rakchha Chhetri, Sarah Moore, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2021-154523

Published: 2021

Journal Articles

Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups

Rakchha Chhetri, Kirsty Sharplin, William Proudman, Monika M Kutyna, Siddarth Nayar, Deepak Singhal, David M Ross, Michelle Damin, Akash Kalro, Peter G Bardy, Daniel Thomas, Mithun V. Shah, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2021-154094

Published: 2021

Journal Articles

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Rakchha Chhetri, MBBS, Oisin Friel, MBBS, Monika M Kutyna, MSc, Kathleen Pao Lynn Cheok, MBBS, Li Yan A Wee, BSc (Hons), Hossam Amin, Rebecca Thompson, B Pharm, Deepak Singhal, MBBS,MDFRACP,FRCPA, Kirsty M Sharplin, MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143319

Published: 2020

Journal Articles

Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair

Monika M Kutyna, MSc, Li Yan A Wee, BSc (Hons), Sharon Paton, BSc, Dimitrios Cakouros, PhD, Agnieszka Arthur, PhD, Rakchha Chhetri, MBBS, Andreas W Schreiber, PhD, Chung Hoow Kok, PhD BSc, Deepak Singhal, MBBS,MDFRACP,FRCPA, Daniel Thomas, MD PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David Campbell, PhD B.M.B.S., F.R.A.C.S., F.A.Oth.A, Stan Gronthos, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137277

Published: 2020

Journal Articles

Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)

Monika M Kutyna, MSc, Amilia Wee, BSc (Hons), Sharon Paton, BSc, Dimitrios Cakouros, PhD, Agnes Arthur, PhD, Rakchha Chhetri, MBBS, Deepak Singhal, MBBS, MD FRACP, FRCPA, Stan Gronthos, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 1694.

https://doi.org/10.1182/blood-2019-126457

Published: 2019

Journal Articles

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Angela Molga, MBBS, Michelle Wall, Dip HE (Nursing), BA (Hons), MSc, PG Cert, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Deepak Singhal, MBBS, MDFRACP, FRCPA, Pratyush Giri, MBBS,FRACP,FRCPA, Timothy To, BSc, BMBS, FRACP, FAChPM, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 5426.

https://doi.org/10.1182/blood-2019-132164

Published: 2019

Journal Articles

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Blood (2019) 134 (Supplement_1): 1704.

https://doi.org/10.1182/blood-2019-126462

Published: 2019

NARROW

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy

T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML

Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome

Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS

Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair

Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only